Mannkind (MNKD) Shares Outstanding (Diluted Average) (2020 - 2026)
Mannkind (MNKD) reported Shares Outstanding (Diluted Average) of $308.3 million for Q1 2026, down 3.94% year-over-year from $320.9 million in Q1 2025, and down 1.86% on a QoQ basis from $314.1 million in Q4 2025.
Mannkind (MNKD) has 7 years of Shares Outstanding (Diluted Average) data on file, last reported at $308.3 million in Q1 2026.
- Quarterly Shares Outstanding (Diluted Average) fell 3.94% year-over-year to $308.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $308.3 million (down 3.94% YoY) and the FY2025 annual result came in at $314.1 million, up 10.66% from the prior year.
- Shares Outstanding (Diluted Average) declined to $308.3 million in Q1 2026 per MNKD's latest filing, from $314.1 million in the prior quarter.
- Across five years, Shares Outstanding (Diluted Average) topped out at $324.7 million in Q1 2024 and bottomed at $251.9 million in Q1 2022.
- The 5-year median for Shares Outstanding (Diluted Average) is $281.4 million (2024), against an average of $287.0 million.
- The widest annual swing landed in 2023, when Shares Outstanding (Diluted Average) advanced 24.86%; it then dropped 13.08% in 2024.
- Tracing MNKD's Shares Outstanding (Diluted Average) over 5 years: stood at $257.1 million in 2022, then increased by 3.86% to $267.0 million in 2023, then climbed by 6.3% to $283.8 million in 2024, then advanced by 10.66% to $314.1 million in 2025, then slipped by 1.86% to $308.3 million in 2026.
- Per Business Quant, the three latest MNKD Shares Outstanding (Diluted Average) figures stand at $308.3 million (Q1 2026), $314.1 million (Q4 2025), and $313.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 138.23 Mn |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn | 308.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 308.27 Mn |
| Dec 31, 2025 | 314.11 Mn |
| Sep 30, 2025 | 313.34 Mn |
| Jun 30, 2025 | 312.38 Mn |
| Mar 31, 2025 | 320.90 Mn |
| Dec 31, 2024 | 283.84 Mn |
| Sep 30, 2024 | 281.41 Mn |
| Jun 30, 2024 | 279.36 Mn |
| Mar 31, 2024 | 324.73 Mn |
| Dec 31, 2023 | 267.01 Mn |
| Sep 30, 2023 | 323.77 Mn |
| Jun 30, 2023 | 264.80 Mn |
| Mar 31, 2023 | 263.97 Mn |
| Dec 31, 2022 | 257.09 Mn |
| Sep 30, 2022 | 259.30 Mn |
| Jun 30, 2022 | 253.64 Mn |
| Mar 31, 2022 | 251.89 Mn |
| Dec 31, 2021 | 249.24 Mn |
| Sep 30, 2021 | 248.62 Mn |
| Jun 30, 2021 | 247.97 Mn |
| Dec 31, 2020 | 222.59 Mn |